.BIOTRONIK US has announced that it has concluded the BIO-OSCAR SOC study evaluating the baseline against which to measure the Oscar multifunctional catheter in treating complex PAD. The outcomes were presented at the Paris Vascular Insights Course 2024 by Koen Deloose vascularspecialistonline.com/bio-oscar-soc-…

Get ready for the must-have tool in #vascular surgery! 🌟 The #PVI Trials Book 2024 features a rigorous selection of trials, studies, RCTs and meta-analyses, offering key results and take-home messages for better decision-making. 📚 Available soon online—don’t miss it!

Clash of the Titans: clinically based PAD debates 📹 In this PVI Course 2024 session replay, experts discuss the best approaches to treating aorto-iliac occlusive disease—angioplasty, stenting, or specific stent types. View #PVI Course replay 👉🏼 paris-vascular-insights.com/cases-resource…

🎥 In this PVI Course 2024 session dedicated to LBTs, experts share recent findings on lower extremity treatments. View replay 👉🏼 ow.ly/RI3V50Uu8bg #vascular #endovascular #vascularsurgery #PVI24

Het mocht eens gezegd worden...

Unlocking the potential of the Oscar Multifunctional Catheter 🙌🏼 In this exclusive #PVI 2024 interview, Dr. Koen Deloose shares how Oscar improves lesion crossing, boosts success rates, and enhances preparation efficiency in #vascular intervention. ➡️ ow.ly/SHoZ50UCEkh

Are you coming to the LINC Symposium Leipzig 2025? 🧐 Come and meet the Paris Vascular Insights team to learn more about the #PVI Course 2025! Plus, get a chance to win your ticket to the leading #vascular course 🎁 🍀 Try your luck now 👉🏼 ow.ly/WmqK50UOIVN

Dr Koen Deloose presented new subanalysys of the 5-year outcomes of TINTIN trial showing long term results of the TINTIN technique (Luminor + iVolution pro) in long and complex lesions. Diference was only observed in claudicant patients, reenforcing its efficacy. #LINC2025

How to treat BTK lesions? The BIBIOS Trial confirms that Luminor DCB is both effective and safe even in BTK lesions. At #LINC2025, Koen Deloose presented the key findings: ✅88.6% freedom from TLR at 1 year ✅ No significant differences between subgroups #Endovascular

Nikolas De Meurechy 1 j geleden.... wat een hypocrisie 🤮

P R O F I C I A T !!! N-VA Bart De Wever Louis Ide Unknown alias We keep it in mind….. wat een hypocrisie…🤮🤢🤮

Isabelle Van Herzeele, Adrien Hertault and their great team already gathered to work on the hands-on sessions for #PVI 2025! ✨ Stay tuned for #PVI25, 11-13 December 2025 🚀 #vascular #endovascular

Louis Ide Eva De Bleeker De Zondag N-VA Louis, het lijkt me best dat de partijtop van NVA niet te veel meer van de toren gaat blazen over de GHZ, gezien jullie VDB een 2e termijn gegeven hebben én akkoord gaan met de verstaatsing van de zorg. Best zwijgen, tenzij jullie eens gaan antworden op zorgverleners hun zorgen.

At #IMENDOForum, Dr Deloose exposed the outstanding effects regarding the efficacy and safety of Luminor DCB even in BTK lesions. The BIBLIOS Trial confirmed Luminor’s efficacy with an 86.6% fTLR at 1 year and no significant differences between subgroups.

🌍 60+ countries. One epic gathering. Let’s do it again! 📆 PVI Course 2025 will take place from December 11 to 13 in Paris, France! Expect cutting-edge science, game-changing discussions, and networking that truly matters. Register now! 👉🏻 ow.ly/iszG50VxtqA

Step into vascular innovation at #PVI 2025! 🚀 Fresh from CIRSE, our experts bring invaluable scientific exchanges and insights – and you’ll get the chance to experience it all firsthand at PVI. 👨🏻‍⚕️ Register now! 🚨 ➡️ brnw.ch/21wW53r

We onderhandelen momenteel met de ziekenfondsen over 900mio besparingen in het budget gezondheidszorg - deel reeds beslist - voor de begroting 2026. Hierbij moeten we als artsen 150mio vinden en moet er 50mio in het dagziekenhuis gevonden worden. Ziekenfondsen nemen de lead

🧵Ever wonder why some microcatheters feel more flexible, torqueable, or pushable than others? The secret often lies in their braid design. Let’s break down microcatheter braiding, why it matters, and how variations affect performance! 👇

🔥 Save the Date! Exclusive webinar PVI 🖥️ Join top experts Koen Deloose, Yann Gouëffic, Eric Secemsky, and Joachim Nordanstig to discuss the latest updates and implications around the SWEDEPAD 2 trial. 🗓 October 21st | 5:30–6:00 PM CET ✨ Free registration — opening soon!

SWEDEPAD 2 changed the game! 🙌🏼 Join Deloose, Gouëffic, Nordanstig & Secemsky live from the #PVI Studio for a 30-min debate on what’s next for #vascular practice. 🚀 📅 Oct 21 | 🕠 17:30 CET Register for free 👉🏼 brnw.ch/21wWGga